Fatih Ezgu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fatih Ezgu has a total of 317 co-authors. Here are the top co-authors by number of shared publications:
- Aslı İnci
Department of Pediatric Nutrition and Metabolism, School of Medicine, Gazi University, Ankara 06500, Türkiye
11 shared publications - Leyla Tümer
Department of Pediatrics, Division of Pediatric Metabolism, Gazi University Faculty of Medicine, Ankara 06500, Türkiye
11 shared publications İlYas Okur
Department of Pediatric Metabolism Gazi University Faculty of Medicine Ankara Turkey
7 shared publications- Filiz Başak Cengiz Ergin
Division of Pediatric Genetics, Department of Pediatrics Faculty of Medicine, Gazi University Ankara Türkiye
6 shared publications İlyas Okur
GAZİ ÜNİVERSİTES
6 shared publicationsLeyla Tümer
Department of Pediatric Metabolism Gazi University Faculty of Medicine Ankara Turkey
6 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (6)
Clinical History and Burden of Gaucher Disease Type 3: A Cross‐Sectional Multinational Study
Gaucher disease Type 3 (GD3) is a rare genetic neurodegenerative disorder, characterized by heterogeneity in symptom burden, disease severity, and progression. There is limited evidence on the burden of GD3. This retrospective, cross‐sectional study estimated the burden of illness associated with GD3 using descriptive analyses of clinician‐ and patient/caregiver‐reported data from Germany, Italy, Spain, Turkey, the UK, and the US. A total of 79 patients were enrolled in the study; 39 patients and 38 caregivers completed the patient/caregiver survey. The majority of patients were male (74.7%) and under 18 years old (55.7%), with an average age at index (study enrolment date) of 17.0 years (SD = 9.0). Patients received a GD3 diagnosis at a mean age of 8.2 years (SD = 6.4). The most common first non‐neurological symptoms experienced were splenomegaly (49.4%), anemia (44.3%), and enlarged abdomen (43.0%), while the first most common neurological manifestations reported included eye movement disorders (54.4%), epilepsy (35.4%), and neurodevelopmental delay (34.2%). Approximately half of patients experienced falls (55.7%) or difficulty with personal care (53.2%). Nearly half of patients (45.6%) had at least one hospitalization, with a mean (SD) of 2.1 (1.7) hospitalizations per patient, in the 2 years pre‐index. Caregivers were predominantly female (86.8%) and provided an average of 63.3 h of care per week (SD = 40.2). They reported high work impairment (70.3%, SD = 22.0; WPAI) and reduced quality of life (CarerQoL‐7D mean = 67.0, SD = 15.8). This study characterizes the real‐world burden of GD3, providing an up‐to‐date, multinational perspective on its clinical history and impact on patients, caregivers, healthcare systems, and society.
- 30 October 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (6)
Open AccessClinical History and Burden of Gaucher Disease Type 3: A Cross‐Sectional Multinational Study
Gaucher disease Type 3 (GD3) is a rare genetic neurodegenerative disorder, characterized by heterogeneity in symptom burden, disease severity, and progression. There is limited evidence on the burden of GD3. This retrospective, cross‐sectional study estimated the burden of illness associated with GD3 using descriptive analyses of clinician‐ and patient/caregiver‐reported data from Germany, Italy, Spain, Turkey, the UK, and the US. A total of 79 patients were enrolled in the study; 39 patients and 38 caregivers completed the patient/caregiver survey. The majority of patients were male (74.7%) and under 18 years old (55.7%), with an average age at index (study enrolment date) of 17.0 years (SD = 9.0). Patients received a GD3 diagnosis at a mean age of 8.2 years (SD = 6.4). The most common first non‐neurological symptoms experienced were splenomegaly (49.4%), anemia (44.3%), and enlarged abdomen (43.0%), while the first most common neurological manifestations reported included eye movement disorders (54.4%), epilepsy (35.4%), and neurodevelopmental delay (34.2%). Approximately half of patients experienced falls (55.7%) or difficulty with personal care (53.2%). Nearly half of patients (45.6%) had at least one hospitalization, with a mean (SD) of 2.1 (1.7) hospitalizations per patient, in the 2 years pre‐index. Caregivers were predominantly female (86.8%) and provided an average of 63.3 h of care per week (SD = 40.2). They reported high work impairment (70.3%, SD = 22.0; WPAI) and reduced quality of life (CarerQoL‐7D mean = 67.0, SD = 15.8). This study characterizes the real‐world burden of GD3, providing an up‐to‐date, multinational perspective on its clinical history and impact on patients, caregivers, healthcare systems, and society.
- 8 October 2026
- Published by Wiley in Clinical Genetics
A Homozygous ALCAM–CBLB Deletion at 3q13.11‐q13.12 Defines a Candidate Novel Oculo‐Skeletal‐Immune Contiguous Gene Deletion Syndrome
To our knowledge, we report the first combined homozygous deletion of ALCAM and CBLB at 3q13.11‐q13.12. The patient, a 14‐year‐old boy born to consanguineous parents, had a multisystem phenotype with severe congenital ocular and craniofacial anomalies, early‐onset osteoporosis, progressive scoliosis, growth failure, congenital heart defect, humoral immunodeficiency, and chronic inflammatory findings. SNP array identified a 2.5‐Mb homozygous deletion spanning ALCAM and CBLB , and expression studies confirmed complete absence of ALCAM and CBLB expression. Whole‐exome sequencing did not identify an alternative molecular diagnosis. The clinical presentation is likely attributable to combined ALCAM and CBLB loss. Previous animal‐model studies support interpretation of the individual phenotypic components by linking loss of these genes to craniofacial developmental abnormalities, skeletal findings, and immune dysregulation. We propose that this deletion may represent a candidate novel contiguous gene deletion syndrome. This case is the first human phenotype associated with complete ALCAM loss in a contiguous deletion and expands the clinical spectrum associated with disruption of ALCAM and CBLB .
- 8 October 2026
- Published by Wiley in Clinical Genetics
A Homozygous ALCAM–CBLB Deletion at 3q13.11‐q13.12 Defines a Candidate Novel Oculo‐Skeletal‐Immune Contiguous Gene Deletion Syndrome
To our knowledge, we report the first combined homozygous deletion of ALCAM and CBLB at 3q13.11‐q13.12. The patient, a 14‐year‐old boy born to consanguineous parents, had a multisystem phenotype with severe congenital ocular and craniofacial anomalies, early‐onset osteoporosis, progressive scoliosis, growth failure, congenital heart defect, humoral immunodeficiency, and chronic inflammatory findings. SNP array identified a 2.5‐Mb homozygous deletion spanning ALCAM and CBLB , and expression studies confirmed complete absence of ALCAM and CBLB expression. Whole‐exome sequencing did not identify an alternative molecular diagnosis. The clinical presentation is likely attributable to combined ALCAM and CBLB loss. Previous animal‐model studies support interpretation of the individual phenotypic components by linking loss of these genes to craniofacial developmental abnormalities, skeletal findings, and immune dysregulation. We propose that this deletion may represent a candidate novel contiguous gene deletion syndrome. This case is the first human phenotype associated with complete ALCAM loss in a contiguous deletion and expands the clinical spectrum associated with disruption of ALCAM and CBLB .
- 16 September 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70700
Hemophagocytic Lymphohistiocytosis in a Patient With Gaucher Disease Having a Homozygous STXBP3 Variant
- 16 September 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70700
Hemophagocytic Lymphohistiocytosis in a Patient With Gaucher Disease Having a Homozygous STXBP3 Variant
- 6 August 2026
- Published by Wiley in Clinical Endocrinology
- Vol. 105 (6) , 651-659
Self‐Reported Health Burden and Quality‐of‐Life–Related Concerns in Patients With Achondroplasia: A Survey From Türkiye
Objective: Achondroplasia is an autosomal dominant genetic disorder, characterised by distinctive growth patterns and recognisable skeletal features. This study aimed to determine the demographic and clinical characteristics, quality of life (QoL) losses, and expectations of individuals with achondroplasia in Türkiye. Design: In this survey‐based study, Computer‐Assisted Telephone Interviewing (CATI) system was used and questions were directed to patients or their parents via phone calls. Patients: A total of 140 patients with achondroplasia, of whom 50.7% were male (age range, 0–20 years) were included. Measurements: The questionnaire forms were prepared by a committee including clinicians and the president of the Achondroplasia and Families Association. The forms included questions on sociodemographic characteristics, diagnosis and treatment, expectations from the patient association, and quality of life. Results: Achondroplasia was commonly diagnosed by obstetricians (76.5%) and the patients were followed by multiple specialties. Of the patients, 10% received growth hormone treatment, and 55.7% underwent at least one surgical procedure, with 23.6% undergoing limb lengthening surgery. The main symptoms frequently/very frequently observed in the patients were: sleep‐disordered breathing (40%), recurrent ear infections (32%), and frequent respiratory tract infections (28%). The primary concerns involved experiences of social exclusion due to physical appearance and together with related psychological challenges. The main expectations of the participants and parents from the association were to receive education on achondroplasia management and new treatment options, and to promote public awareness. Conclusions: Patients with achondroplasia face significant challenges in daily life, they require medical treatment and some supportive services to improve their quality of life.
- 6 August 2026
- Published by Wiley in Clinical Endocrinology
- Vol. 105 (6) , 651-659
Self‐Reported Health Burden and Quality‐of‐Life–Related Concerns in Patients With Achondroplasia: A Survey From Türkiye
Objective: Achondroplasia is an autosomal dominant genetic disorder, characterised by distinctive growth patterns and recognisable skeletal features. This study aimed to determine the demographic and clinical characteristics, quality of life (QoL) losses, and expectations of individuals with achondroplasia in Türkiye. Design: In this survey‐based study, Computer‐Assisted Telephone Interviewing (CATI) system was used and questions were directed to patients or their parents via phone calls. Patients: A total of 140 patients with achondroplasia, of whom 50.7% were male (age range, 0–20 years) were included. Measurements: The questionnaire forms were prepared by a committee including clinicians and the president of the Achondroplasia and Families Association. The forms included questions on sociodemographic characteristics, diagnosis and treatment, expectations from the patient association, and quality of life. Results: Achondroplasia was commonly diagnosed by obstetricians (76.5%) and the patients were followed by multiple specialties. Of the patients, 10% received growth hormone treatment, and 55.7% underwent at least one surgical procedure, with 23.6% undergoing limb lengthening surgery. The main symptoms frequently/very frequently observed in the patients were: sleep‐disordered breathing (40%), recurrent ear infections (32%), and frequent respiratory tract infections (28%). The primary concerns involved experiences of social exclusion due to physical appearance and together with related psychological challenges. The main expectations of the participants and parents from the association were to receive education on achondroplasia management and new treatment options, and to promote public awareness. Conclusions: Patients with achondroplasia face significant challenges in daily life, they require medical treatment and some supportive services to improve their quality of life.
- Open Access
Transcriptomic Profiling of Monozygotic Twins with Type 1 Gaucher Disease
Background: Gaucher disease (GD) arises from pathogenic variants in the GBA1 gene and is known for its wide range of clinical presentations—a variability that genotype alone cannot adequately account for. Objective: This study aimed to explore transcriptomic factors that might help explain why two genetically identical twins with type 1 GD developed noticeably different clinical outcomes. Methods: We isolated peripheral blood mononuclear cells from both twins and two age-matched controls, then differentiated them into macrophages in vitro before conducting RNA sequencing. Gene expression differences were analyzed using established bioinformatics pipelines, and a subset of genes were subsequently assessed by quantitative real-time PCR (qRT-PCR) to confirm the sequencing findings. Results: Both twins shared a GD-associated transcriptional signature broadly reflecting immune activation and lysosomal stress. Interestingly, the twin who experienced systemic complications had a relative enrichment of interferon-responsive transcripts, while the less severely affected twin showed more pronounced suppression of small nucleolar RNA clusters. That said, neither difference held up after correcting for multiple comparisons, so these patterns are best viewed as exploratory trends rather than definitive findings. The qRT-PCR results lend partial support to this picture: stress- and immune-related genes (DDIT4, RPH3A, SAMSN1) trended toward higher expression in patients versus controls, and interferon-stimulated genes (ISG15, RSAD2, IFI44L) were more elevated in M2 than in M1. Conclusions: Taken together, these findings suggest that factors beyond genetics—whether epigenetic, environmental, or otherwise—may play a meaningful role in shaping how GD manifests differently even between individuals with identical DNA. Although the data are preliminary, they point to transcriptomic profiling, paired with targeted validation, as a useful starting point for building hypotheses about why this disease looks so different from one patient to the next, even when the underlying mutation is the same.
Open AccessTranscriptomic Profiling of Monozygotic Twins with Type 1 Gaucher Disease
Background: Gaucher disease (GD) arises from pathogenic variants in the GBA1 gene and is known for its wide range of clinical presentations—a variability that genotype alone cannot adequately account for. Objective: This study aimed to explore transcriptomic factors that might help explain why two genetically identical twins with type 1 GD developed noticeably different clinical outcomes. Methods: We isolated peripheral blood mononuclear cells from both twins and two age-matched controls, then differentiated them into macrophages in vitro before conducting RNA sequencing. Gene expression differences were analyzed using established bioinformatics pipelines, and a subset of genes were subsequently assessed by quantitative real-time PCR (qRT-PCR) to confirm the sequencing findings. Results: Both twins shared a GD-associated transcriptional signature broadly reflecting immune activation and lysosomal stress. Interestingly, the twin who experienced systemic complications had a relative enrichment of interferon-responsive transcripts, while the less severely affected twin showed more pronounced suppression of small nucleolar RNA clusters. That said, neither difference held up after correcting for multiple comparisons, so these patterns are best viewed as exploratory trends rather than definitive findings. The qRT-PCR results lend partial support to this picture: stress- and immune-related genes (DDIT4, RPH3A, SAMSN1) trended toward higher expression in patients versus controls, and interferon-stimulated genes (ISG15, RSAD2, IFI44L) were more elevated in M2 than in M1. Conclusions: Taken together, these findings suggest that factors beyond genetics—whether epigenetic, environmental, or otherwise—may play a meaningful role in shaping how GD manifests differently even between individuals with identical DNA. Although the data are preliminary, they point to transcriptomic profiling, paired with targeted validation, as a useful starting point for building hypotheses about why this disease looks so different from one patient to the next, even when the underlying mutation is the same.
- Top Cited PapersOpen Access
- 12 January 2026
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (4) , 101683
Effect of long-term sepiapterin treatment on dietary phenylalanine tolerance in patients with phenylketonuria: Interim results from the phase 3 APHENITY Extension Study
- 12 January 2026
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (4) , 101683
Top Cited PapersOpen AccessEffect of long-term sepiapterin treatment on dietary phenylalanine tolerance in patients with phenylketonuria: Interim results from the phase 3 APHENITY Extension Study
- Open Access
- 4 December 2025
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 18 (2) , 282-287
Mucopolysaccharidosis or Skeletal Dysplasia?: Important Clinical and Radiologic Clues for Differential Diagnosis of Based on Difficult Cases
Mucopolysaccharidosis or Skeletal Dysplasia?: Important Clinical and Radiologic Clues for Differential Diagnosis of Based on Difficult Cases - Journal of Clinical Research in Pediatric Endocrinology
- 4 December 2025
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 18 (2) , 282-287
Open AccessMucopolysaccharidosis or Skeletal Dysplasia?: Important Clinical and Radiologic Clues for Differential Diagnosis of Based on Difficult Cases
Mucopolysaccharidosis or Skeletal Dysplasia?: Important Clinical and Radiologic Clues for Differential Diagnosis of Based on Difficult Cases - Journal of Clinical Research in Pediatric Endocrinology
- Open Access
- 1 October 2025
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 146 (3) , 109248
Unmet needs in the treatment and care of somatic manifestations in mucopolysaccharidosis type II: A targeted literature review
- 1 October 2025
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 146 (3) , 109248
Open AccessUnmet needs in the treatment and care of somatic manifestations in mucopolysaccharidosis type II: A targeted literature review
- Open Access
- 5 September 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (9) , 1-2
Correction to: Clinical, laboratory and molecular features of glycogen storage disease type 1a and 1b patients from Turkey: novel mutations and phenotypes
- 5 September 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (9) , 1-2
Open AccessCorrection to: Clinical, laboratory and molecular features of glycogen storage disease type 1a and 1b patients from Turkey: novel mutations and phenotypes
- Open Access
- 20 June 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (3) , 585-594
Expert opinion on clinical presentation, diagnosis and treatment of infantile onset pompe disease: a delphi study in Türkiye
Background/aim: Pompe disease (acid maltase deficiency, glycogen storage disease type II, OMIM #606800) is an autosomal recessive disorder characterized by lysosomal acid-α-glucosidase deficiency. The infantile-onset type of the disease is mainly characterized by cardiomegaly, hypotonia, and a high mortality rate. This study aimed to create a national consensus about infantile-onset Pompe disease (IOPD) to raise awareness among clinicians and standardize diagnosis and treatment approaches in Türkiye. Materials and methods: The Gazi University Division of Metabolic Diseases and Nutrition developed this expert opinion consensus and expanded it to include metabolism specialists across Türkiye. A systematic literature review was performed, and the Delphi method was used to evaluate the results. Results: Seventeen conclusive questions were produced about clinical presentation, diagnosis, and treatment, and 14 reached a consensus. Consensus was reached that general hypotonia is one of the most important findings, and agreement was also achieved on the starting dose of treatment for presymptomatic patients. The contributors agreed that gene therapy is a good treatment option for IOPD in the future. Conclusion: The topics related to this consensus will help physicians in Türkiye and elsewhere with high incidence rates of IOPD,especially regarding diagnosis and treatment decisions.
- 20 June 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (3) , 585-594
Open AccessExpert opinion on clinical presentation, diagnosis and treatment of infantile onset pompe disease: a delphi study in Türkiye
Background/aim: Pompe disease (acid maltase deficiency, glycogen storage disease type II, OMIM #606800) is an autosomal recessive disorder characterized by lysosomal acid-α-glucosidase deficiency. The infantile-onset type of the disease is mainly characterized by cardiomegaly, hypotonia, and a high mortality rate. This study aimed to create a national consensus about infantile-onset Pompe disease (IOPD) to raise awareness among clinicians and standardize diagnosis and treatment approaches in Türkiye. Materials and methods: The Gazi University Division of Metabolic Diseases and Nutrition developed this expert opinion consensus and expanded it to include metabolism specialists across Türkiye. A systematic literature review was performed, and the Delphi method was used to evaluate the results. Results: Seventeen conclusive questions were produced about clinical presentation, diagnosis, and treatment, and 14 reached a consensus. Consensus was reached that general hypotonia is one of the most important findings, and agreement was also achieved on the starting dose of treatment for presymptomatic patients. The contributors agreed that gene therapy is a good treatment option for IOPD in the future. Conclusion: The topics related to this consensus will help physicians in Türkiye and elsewhere with high incidence rates of IOPD,especially regarding diagnosis and treatment decisions.